Europe Market for Mechanical Thrombectomy 2017 - MedCore
General Report Contents
Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
Market Drivers & Limiters for each chapter segment
Competitive Analysis for each chapter segment
Section on recent mergers & acquisitions
There will be significant market growth in the mechanical thrombectomy market over the forecast period, driven by growth in unit sales as mechanical thrombectomy is adopted as standard of care for acute ischemic stroke patients.
This market includes stent retrievers and suction thrombectomy catheters. The majority of the time a combination of the two categories is used but there a number of factors that can impact treatment decisions, one key factor being physician preference. Studies found new stent retriever devices are superior to first generation aspiration devices but there have been fewer studies comparing the second generation of both categories. There had been a strong evolution in Europe towards combination of aspiration and stent retriever but now the market is moving even farther towards aspiration only techniques. Both categories of devices have are required in specific cases as certain devices appear to more successful based on the anatomy, clot morphology and clot locations. There has been huge variability on reported success rates with aspiration-only which influences the frequency that a stent retriever is required in combination. Additional clinical trials will influence whether the devices continue to be used in conjunction or whether one category will cannibalize shares form the other.
The ASP of both categories of devices is expected to remain stable over the forecast period. The stent retriever drives the market value higher quicker due to the higher ASP it commands and the need for more than one device per procedure.
Ischemic Stroke is caused by an obstruction within a blood vessel that is supplying blood to the brain. This is often caused by blood clots but can also be caused by other substances like plaques. The gold standard treatment for strokes for many years has been the administration of clot dissolving or clot busting medication called tissue plasminogen activator (tPA). This type of drug must be administered as soon as possible, with a four hour window from symptom onset, to increase chances of recovery. A significant number of patients do not get to healthcare facilities quickly enough to meet that window and even some of those who do, later experience hemorrhagic complications from the medication. It is very effective for smaller clots but often fails to break up larger clots. Some patients cannot receive tPA, in which cases physicians rely on antiplatelet or anticoagulant medicine to ensure blood clots do not get larger.